Company profile

Elixira company profile

Elixira is open for licensing partnerships. Invented and founded by Tess Fries, Elixira is a patent-pending, AI-guided nanobot platform designed as a one-time injection for lifelong, autonomous prevention across all cancer types. Its technical feasibility has been independently reviewed by a world-leading European Contract Research Organization (CRO), and all core technologies underlying Elixira are based on validated and peer-referenced scientific principles. A detailed technical feasibility report is available to prospective partners under NDA. Developed on in vivo–proven nanotechnology and biomedical-engineering foundations, Elixira integrates self-sustaining hybrid-energy systems and multiple elimination methods to enable a proactive, continuous prevention model. Operating autonomously inside..... For more information, log in to dureach.com to view the full company profile.

Business identity

Contact email
[email protected]
Operating status
Active
Company type
For Profit
Employee range
00001-00010 employees
Founded
2025-07-03

Headquarters

Headquarters
Lund, Skane Lan, Sweden
Postal code
22476
Country code
SE
Continent
Europe

Capital profile

Funding and company signals

Founders
1
Articles
518

Founders and investors

Founders

Tess Fries

People at this company

Preview only. Contact details are available after you sign in.

Log in to view people and contact details at this company

Contact information and company affiliations may no longer be accurate. Verify details before reaching out.

Shipment data

Explore detailed shipment data

Sign in to view shipment history, products, suppliers, and trade lanes for this company.

Log in to view shipment data

Shipment records and coverage can change as the dataset is updated.